In the landscape of modern drug discovery, a quiet but profound revolution is taking place. For decades, the pathology slide was viewed as a terminal asset—a piece of glass to be examined, reported upon, and eventually consigned to a storage archive. Today, that paradigm is shifting. Driven by the rapid maturation of digital pathology and the integration of artificial intelligence (AI), researchers are transforming these dormant archives into goldmines of actionable biological data.
This transformation is not merely a technological upgrade; it is a critical pillar in the global movement to minimize, refine, and replace animal testing in preclinical safety studies. By "mining" existing tissue samples and leveraging virtual control groups, scientists are finding ways to extract more scientific value from every animal used in a study, effectively reducing the need for future experiments.
The Chronology of a Paradigm Shift
The ascent of digital pathology was accelerated by necessity. During the COVID-19 pandemic, the physical isolation of pathologists forced a rapid, industry-wide adoption of digital slide scanning. What began as a stop-gap measure to ensure business continuity quickly revealed an unforeseen benefit: once tissue is digitized, it becomes a permanent, searchable, and shareable data asset.
- Pre-2020: Pathology was a "one-way street." Slides were physical entities, and data extraction was limited to the human eye’s ability to interpret morphological changes.
- 2020–2022: The pandemic forces the digitization of workflows. Pathologists begin working remotely, and the infrastructure for high-resolution, cloud-accessible pathology images matures.
- 2022: The FDA Modernization Act 2.0 is enacted in the United States, signaling a legislative shift toward accepting non-animal methods (NAMs) in drug development pipelines.
- 2024: Charles River Laboratories launches its Alternative Methods Advancement Project, focusing on systematic ways to reduce reliance on live animal models.
- 2025–2026: Regulatory bodies, including the FDA and OECD, release formal roadmaps and guidance on sample collection for "omics" and the use of New Approach Methodologies (NAMs), signaling that animal-free or animal-reduced testing is moving from an experimental goal to a regulatory standard.
Mining the Past: The Value of Archived FFPE Tissue
In standard toxicology studies, tissue samples are typically preserved as formalin-fixed, paraffin-embedded (FFPE) blocks. These blocks have traditionally been treated as archival waste once the primary study report is filed. However, as Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories, points out, "Before, the pathology endpoint was just a report. Now you have the digitized slide, which is pixels."
These pixels are no longer static images; they are data-rich inputs for machine learning models. By pairing digitized slides with original pathology reports and molecular measurements, researchers can train algorithms to identify subtle patterns—molecular changes that might have been invisible to the human eye or overlooked during the initial study.
Furthermore, the physical FFPE blocks remain available for retrospective molecular analysis. If a researcher discovers a potential side effect or a specific biological pathway of interest years after a study concludes, they can return to the archived blocks to perform gene expression or protein studies. This avoids the ethical and financial cost of launching a new animal study to answer a question that the original samples could have addressed.
Virtual Control Groups: Reducing Animal Burden Through Arithmetic
One of the most compelling applications of data-mining in preclinical research is the implementation of "virtual control groups." In traditional toxicology, a significant portion of animal subjects are designated as controls to provide a baseline for comparison against drug-treated groups.
"Control animals are always a big fraction of every study," notes Dr. Zuraw. By curating high-quality, matched historical data, researchers can create virtual control groups that serve the same statistical purpose as a concurrent group of live animals. If the baseline biological markers are sufficiently consistent across comparable study conditions, the necessity of housing and sacrificing additional control animals is eliminated.
The challenge lies in rigor. Establishing that historical data is truly "comparable" to the present study requires sophisticated statistical frameworks. Charles River and other leading research organizations are currently building the infrastructure to generate the massive, standardized datasets required to make virtual controls a reliable, repeatable feature of regulatory submissions.
Supporting Data and Technical Innovations
The move toward digital efficiency is bolstered by several converging technical trends. One of the most significant is molecular prediction from hematoxylin and eosin (H&E) staining. H&E is the gold standard for visual tissue analysis. Recent advancements have demonstrated that deep learning models can "read" these images to predict molecular states—such as gene expression profiles—that previously required expensive and time-consuming laboratory assays.
Then there is the emergence of virtual staining. This cutting-edge process involves scanning an unstained tissue section and using software to generate a digital, stained image. This removes the need for physical chemical staining and can, in some instances, bypass the need for physical glass slides altogether. While currently in the early stages of clinical and research integration, virtual staining represents the next frontier in "greening" the histology lab.
According to the 2025 OECD guidance on sample collection, the shift toward digitized, multi-omic analysis of archived tissue is not just an ethical imperative; it is an improvement in scientific quality. By standardizing how samples are prepared and stored, researchers can ensure that data remains interpretable for future investigations, creating a long-term "data ecosystem" rather than a series of disconnected, one-off experiments.
Regulatory Implications and the Path Forward
The regulatory environment is no longer just permitting innovation; it is demanding it. The FDA’s April 2025 roadmap for reducing animal testing in preclinical safety studies provides a clear, time-bound trajectory. The agency has prioritized monoclonal antibodies as the initial target for reduction, with plans to expand to other biologics and, eventually, new chemical entities.
The ultimate goal, as outlined by the FDA, is to make animal studies the exception, not the rule. However, as Dr. Zuraw emphasizes, the transition will rely on "early adopters." These organizations must demonstrate that virtual controls and AI-driven pathology analysis can meet or exceed the safety standards of traditional methods. By troubleshooting these processes today, they are building the precedents that will allow the rest of the industry to follow.
Conclusion: A Snowball Effect in Discovery
The transition to a digital-first, data-mining-heavy model of pathology is likely to follow a "snowball effect." As more labs invest in the infrastructure to scan, store, and analyze digital slides, the volume of available data increases, making the training of more powerful AI models possible. This, in turn, makes the tools more useful, encouraging further investment.
We are moving toward an era where the preclinical research cycle is circular rather than linear. By treating archived tissue as a living library of information, the scientific community is fulfilling a dual mission: accelerating the pace of drug discovery while upholding the highest ethical standards for animal welfare. As Dr. Zuraw suggests, the data we need is often already sitting in our archives—we simply lacked the tools to see it. Now, those tools are here, and the potential to reshape drug development is only just beginning to be realized.
About the Author
